A Pilot Trial Evaluating Maintenance Therapy With Lamivudine(Epivir) and Dolutegravir(Tivicay) in Human Immunodeficiency Virus 1 (HIV-1) Infected Patients Virologically Suppressed With Triple HAART - ANRS 167 Lamidol

Trial Profile

A Pilot Trial Evaluating Maintenance Therapy With Lamivudine(Epivir) and Dolutegravir(Tivicay) in Human Immunodeficiency Virus 1 (HIV-1) Infected Patients Virologically Suppressed With Triple HAART - ANRS 167 Lamidol

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Aug 2017

At a glance

  • Drugs Dolutegravir (Primary) ; Lamivudine
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Aug 2017 Status changed from active, no longer recruiting to completed.
    • 10 Jun 2017 Biomarkers information updated
    • 16 Feb 2017 Results presented at the 24th Conference on Retroviruses and Opportunistic Infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top